Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA)

Patent metadata

Field	Value
Publication number	US-9650430-B2
Application number	US-201414452870-A
Country	US
Kind code	B2
Filing date	Aug 6, 2014
Priority date	Aug 17, 1999
Publication date	May 16, 2017
Grant date	May 16, 2017

Abstract

A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

First claim

What is claimed is:

1. A method of inhibiting B-cell growth, immunoglobulin production, or both in a mammal, the method comprising the step of administering to the mammal an effective amount of a BCMA (B-Cell Maturation Antigen) polypeptide, wherein the BCMA polypeptide comprises an amino acid sequence that binds to BAFF (B-Cell Activating Factor of the TNF family; SEQ ID NO:9) and is:
a) at least 95% identical to amino acids 8-41 of SEQ ID NO:1; or
b) at least 95% identical to amino acids 1-51 of SEQ ID NO:1;

and wherein the BCMA polypeptide does not comprise the transmembrane domain of BCMA (amino acids 53-81 of SEQ ID NO:1).

2. The method of claim 1 , wherein the BCMA polypeptide comprises the sequence of amino acids 8-41 of SEQ ID NO:1.

3. The method of claim 1 , wherein the BCMA polypeptide comprises the sequence of amino acids 1-51 of SEQ ID NO: 1.

4. The method of claim 1 , wherein the BCMA polypeptide comprises an Fc domain of an immunoglobulin.

5. The method of claim 4 , wherein the immunoglobulin is IgG.

6. The method of claim 4 , wherein the immunoglobulin is human.

7. The method of claim 1 , wherein the mammal is human.

8. The method of claim 1 , wherein the mammal has inflammation.

9. The method of claim 1 , wherein the mammal has an autoimmune disease.

10. The method of claim 9 , wherein the autoimmune disease is systemic lupus erythematosus.

Assignees

• Biogen Ma Inc
• Topotarget Switzerland Sa
• Biogen Ma Inc

Inventors

• Browning Jeffrey
• Ambrose Christine
• Mackay Fabienne
• Tschopp Jurg
• Schneider Pascal
• Thompson Jeffrey

Classifications

• A61K38/17 Primary

  from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title